Dose-dense effect: other contributors

Affiliations

Comment

S Altug Kesikli et al. Lancet Oncol. 2013 Nov.

. 2013 Nov;14(12):e489.

doi: 10.1016/S1470-2045(13)70466-2.

¹ Department of Basic Oncology, Hacettepe University Cancer Institute, Ankara, Turkey. Electronic address: akesikli@gmail.com.

No abstract available

Comment in

Dose-dense effect: other contributors - author's reply.
Katsumata N. Katsumata N. Lancet Oncol. 2013 Nov;14(12):e489-90. doi: 10.1016/S1470-2045(13)70488-1. Lancet Oncol. 2013. PMID: 24176564 No abstract available.

Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.
Katsumata N, Yasuda M, Isonishi S, Takahashi F, Michimae H, Kimura E, Aoki D, Jobo T, Kodama S, Terauchi F, Sugiyama T, Ochiai K; Japanese Gynecologic Oncology Group. Katsumata N, et al. Lancet Oncol. 2013 Sep;14(10):1020-6. doi: 10.1016/S1470-2045(13)70363-2. Epub 2013 Aug 13. Lancet Oncol. 2013. PMID: 23948349 Clinical Trial.